Form D · Biotechnology
Eiger BioPharmaceuticals, Inc.
Palo Alto, CA · CIK 0001305253
Offering snapshot reported Apr 29, 2016 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 20, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 29, 2016 | Initial | $2,999,982 | No comparison | 1 | SEC filing |
| Oct 25, 2013 | Initial | $1,097,306 | No comparison | 17 | SEC filing |
| May 8, 2012 | Amendment | $19,466,190 | $1,616,194vs Feb 6, 2012 | 24 | SEC filing |
| Feb 6, 2012 | Initial | $17,849,996 | No comparison | 13 | SEC filing |
| Dec 22, 2011 | Initial | $500,000 | No comparison | 6 | SEC filing |
| Nov 16, 2011 | Initial | $330,000 | No comparison | 6 | SEC filing |
| Oct 28, 2011 | Initial | $200,000 | No comparison | 6 | SEC filing |
| Sep 1, 2011 | Initial | $250,000 | No comparison | 6 | SEC filing |
| Jul 12, 2011 | Initial | $400,000 | No comparison | 2 | SEC filing |
| Oct 28, 2010 | Initial | $2,500,000 | No comparison | 7 | SEC filing |
| Dec 17, 2009 | Initial | $3,500,000 | No comparison | 6 | SEC filing |
| Sep 10, 2009 | Amendment | $21,800,002 | No comparison | 6 | SEC filing |
| Apr 1, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 21, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 4, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 28, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-262254
Source: Form D, filed Apr 29, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregg Alton | Director |
| Fouad Azzam | Director |
| Charles Bramlage | Director |
| Kenneth R. Chien | Director |
| Graham Cooper | Director |
| David A. Cory | Director, Executive |
| Barbara Dalton | Director |
| Thomas J. Dietz | Director |
| Edgar G. Engleman | Director |
| Anthony B. Evnin | Director |
| Todd Foley | Director |
| Joshua Funder | Director |
| Jeffrey S. Glenn | Director |
| Nina Kjellson | Director |
| Johan Kordel | Director |
| Rebecque Laba | Executive |
| Eduardo Bruno Martins | Executive |
| Michael Narachi | Director |
| Daniel Omstead | Director |
| Joanne Quan | Executive |
| Andrew E. Senyei | Director |
| James P. Shaffer | Executive |
| Lauren Silverman | Director |
| James H. Welch | Executive |
| Asish Xavier | Director |
| Krisztina Zsebo | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
350 Cambridge Ave Suite 350
Palo Alto, CA, 94306
Palo Alto, CA, 94306